Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Receivables (2018 - 2023)

Moleculin Biotech's Receivables history spans 5 years, with the latest figure at $12000.0 for Q2 2023.

  • Quarterly results put Receivables at $12000.0 for Q2 2023, changed N/A from a year ago — trailing twelve months through Jun 2023 was $12000.0 (changed N/A YoY), and the annual figure for FY2022 was $22000.0, changed.
  • Receivables for Q2 2023 was $12000.0 at Moleculin Biotech, down from $22000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $316000.0 in Q3 2019 to a low of $1000.0 in Q1 2020.
  • The 4-year median for Receivables is $12000.0 (2023), against an average of $72400.0.
  • Peak annual rise in Receivables hit 80.36% in 2019, while the deepest fall reached 80.36% in 2019.
  • Year by year, Receivables stood at $11000.0 in 2019, then plummeted by 90.91% to $1000.0 in 2020, then skyrocketed by 2100.0% to $22000.0 in 2022, then plummeted by 45.45% to $12000.0 in 2023.
  • According to Business Quant data, Receivables over the past three periods came in at $12000.0, $22000.0, and $1000.0 for Q2 2023, Q4 2022, and Q1 2020 respectively.